Full text is available at the source.
Abstract
The use of glucagon-like peptide 1 (GLP-1) receptor agonists has rapidly increased for weight loss management.
- GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists reduce body weight through appetite suppression and metabolic effects.
- These medications are indicated for weight management in patients with obesity as an adjunct to diet and physical activity.
- Access to these weight loss medicines is primarily restricted to higher-risk patients through the NHS.
- A significant number of individuals access weight loss treatments privately, potentially worsening health inequalities related to obesity.
- Risks associated with weight loss medicines include poor dietary quality, muscle loss, and weight regain after treatment cessation.
- Nurses play a critical role in promoting adequate nutrient intake, physical activity, and behavior change to improve long-term patient outcomes.
Simplified